The Global Burden of Diabetes: Case Studies from Guatemala

download The Global Burden of Diabetes: Case Studies from Guatemala

of 37

Transcript of The Global Burden of Diabetes: Case Studies from Guatemala

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    1/37

    The global burden of diabetes: a case study

    from Guatemala

    Peter Rohloff, MD PhD

    Wuqu Kawoq | Maya Health Alliance

    Brigham and Womens Department of Global Health Equities

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    2/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    3/37

    Thirst/fatigue Friend runs a

    lab

    Hyperglycemic

    Fee-for-serviceclinic

    Visual s/s,

    neuropathy

    Pharmacy prn

    NPH injections 1-

    2/wk

    Naturopath

    (I can cure you)

    Fee-for-service

    (met/glyburide

    branded)

    Health Post

    (glimepiride

    generic 1 wk rx)

    Case

    finding/recruit

    ment

    WK | Maya

    Health

    Unemployment/periodic financial

    crisis

    10 years!!

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    4/37

    Global Perspective on NCDs

    63% of global deaths due to NCDs

    80% of global NCD deaths occur in LMICs

    NCD deaths will rise by 20% over next decade

    80% of CVD/DM deaths occur in LMICs

    90% of COPD deaths occur in LMICs

    Two-thirds of cancer deaths occur in LMICs

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    5/37

    Global Perspective on NCDs

    Even in AFR, NCD deaths will exceed maternal/child

    and communicable disease deaths by 2030

    29% of NCD deaths occur in < 60 years in LMICs (13%

    on HICs)

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    6/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    7/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    8/37

    Lancet 2011; 378: 3140

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    9/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    10/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    11/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    12/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    13/37

    Diabetes in Guatemala

    PAHO/CAMDI (2012): 8.4% among urban adults

    Lancet (2011): 8.9%11.5% men; 8%14% women

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    14/37

    BMC Health

    Services

    Research

    2012,

    12:476

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    15/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    16/37

    Knowledge of Diabetes

    Symptoms of hyperglycemia 87% (n = 20)

    Sequelae of end organ damage 43% (n = 10)

    Knowledge of DM prior to diagnosis 39% (n = 9)

    DM as a chronic condition 70% (n = 16)Need for glycemic control 96% (n = 22)

    Glycosylated hemoglobin testing 0%

    Effects of diet on glycemic control 96% (n = 22)

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    17/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    18/37

    Four Core Questions for Global-Rural DM

    Work

    What should a rural DM program look

    like?

    How do you create behavior change?

    What is good control?

    Why do rural/indigenous people get DM?

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    19/37

    Our DM Programa work in progress

    Medication supply chain/formulary

    Free

    Nurses/CHWs (visits q 1-3 months)

    Home visits for family support, diet reinforcement,insulin training

    Protocols for medication titration without MDinvolvement (except insulin)

    Treatment of comorbidities (HTN, proteinuria)

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    20/37

    Elements

    Foot exam (not microfilament)Macroproteinuria (not microalbumin) (q 3-6months)

    Fingerstick glucose

    A1C (q 3-6 months)Serum creatinine (q 6-12 months)

    Blood pressure

    BMI

    Diet counselingInsulin Teaching

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    21/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    22/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    23/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    24/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    25/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    26/37

    What is good control?

    UKPDS newly diagnosed DM, mean age 53. Intensive (A1C7.0) vs standard (A1C 7.9) 12% reduction in all-DM

    endpoint/10% in death mostly (but not all) due to

    microvascular outcomes; changes persisted in ~17 year f/u

    despite loss of tight glycemic control

    ADVANCE Mean duration dx ~ 8 years, mean age 66.

    Reduction in nephropathy with intensive (6.5) vs standard (7.3)

    treatment. No macrovascular benefit. Increased risk of

    death/severe endpoint in subset of intensively treated patientswho were severely hypoglycemic.

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    27/37

    What is good control?

    VADT. Median duration of dx ~ 8 yrs, age 60. Intensive (A1C6.9) vs. standard (8.4) therapy. No difference in micro or

    macrovascular outcomes.

    ACCORD. Median duration of dx ~ 10 yrs, age 62. Intensive

    (A1C 6.4) vs standard (7.5) therapy. Higher rate of CV mortalityin intensive therapy (HR 1.22)

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    28/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    29/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    30/37

    Why do indigenous/rural populations get

    DM?

    Invasion of processed foods

    Changing lifestyles less farming, less manual labor

    Ruralurban migration

    But.

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    31/37

    Why do indigenous/rural populations get

    DM?

    Stunted children develop central adiposity during puberty(Brazil. Nutr. (2007) 23:640)

    Stunted children have impaired insulin production (Brit J Nutr

    (2006) 95:996).

    % body fat is higher in stunted children (Pak J Nutr.(2006)

    4:418 )

    Stunted children have lower BMRs (Eur J Clin Nutr (2005)

    59:835)

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    32/37

    Why do indigenous/rural populations get

    DM?

    Chronic undernutrition in childhood is associated with HTNin adulthood (Mat Child Nutr (2005) 1:155)

    Stunting predicts adult overweight (East Mediterr Health J

    (2009) 15:549

    Short adults have higher serum lipid levels and lower rates of

    fat oxidation (Am J Hum Biol (2009) 21:664

    Short maternal stature predicts maternal obesity, HTN,

    abdominal obesity (Brit J Nutr (2009)101:1239

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    33/37

    www.abc.com

    Damned if you do, damned if you dont: endemic

    undernutrition and the nutrition transition

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    34/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    35/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    36/37

  • 7/28/2019 The Global Burden of Diabetes: Case Studies from Guatemala

    37/37